To verify whether MGP contributes to the therapeutic effect of MSCs in vivo, we established the experimental colitis mouse model with 2,4,6-trinitrobenzene sulfonic acid (TNBS), which shows symptoms similar to clinical CD27,28. This evidence concerns the gene MGP and colitis.